{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-003430","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.282695+00:00","generated_at":"2026-06-01T04:45:00.168556+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioCryst shareholders approve 7M-share increase to Stock Incentive Plan","bullets":["Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.","Directors re-elected: Nancy J. Hutson, Vincent J. Milano, A. Machelle Sanders; broker non-votes 26,962,524.","Ernst & Young ratified as FY 2024 auditor (167,496,029 for); advisory exec-comp resolution passed (138,402,008 for).","Incentive Plan Proposal passed with 101,846,368 for, 43,055,807 against; plan now includes 12-month minimum vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-003430","json":"https://secwatch.observer/filing/0001171843-24-003430.json","markdown":"https://secwatch.observer/filing/0001171843-24-003430.md","text":"https://secwatch.observer/filing/0001171843-24-003430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/0001171843-24-003430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/f8k_061324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:45:00.168556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}